<?xml version="1.0" ?><!--XBRL Document Created with the Workiva Platform--><!--Copyright 2023 Workiva--><!--r:3fc74ccf-9297-43b4-8bd6-d0324616345f,g:2a091e00-480d-4af7-9ce8-bab735938b6e,d:50f9c321473f42f699ab6ffb81ffd1a8--><html xmlns="http://www.w3.org/1999/xhtml" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>kprx-20230612</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i1dae0cffe7ba4799a527dae2c57b0859_D20230612-20230612" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjUwZjljMzIxNDczZjQyZjY5OWFiNmZmYjgxZmZkMWE4L3NlYzo1MGY5YzMyMTQ3M2Y0MmY2OTlhYjZmZmI4MWZmZDFhOF80L2ZyYWc6MTQzMTA2ODI5ZWI4NGMzZTlhNjZiMDA4ZTExYmFiODAvdGFibGU6NGQ5NWIwYTFiYWJkNDRhYWFhMThkZWVkZGM1NjhkNTUvdGFibGVyYW5nZTo0ZDk1YjBhMWJhYmQ0NGFhYWExOGRlZWRkYzU2OGQ1NV8yLTEtMS0xLTQyNjE4_7b264685-00de-4646-a1df-923c26d6f57a">0001372514</ix:nonNumeric><ix:nonNumeric contextRef="i1dae0cffe7ba4799a527dae2c57b0859_D20230612-20230612" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjUwZjljMzIxNDczZjQyZjY5OWFiNmZmYjgxZmZkMWE4L3NlYzo1MGY5YzMyMTQ3M2Y0MmY2OTlhYjZmZmI4MWZmZDFhOF80L2ZyYWc6MTQzMTA2ODI5ZWI4NGMzZTlhNjZiMDA4ZTExYmFiODAvdGFibGU6NGQ5NWIwYTFiYWJkNDRhYWFhMThkZWVkZGM1NjhkNTUvdGFibGVyYW5nZTo0ZDk1YjBhMWJhYmQ0NGFhYWExOGRlZWRkYzU2OGQ1NV8zLTEtMS0xLTQyNjE4_7d56551b-53f4-492d-a437-f9a508398aa2">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="kprx-20230612.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i1dae0cffe7ba4799a527dae2c57b0859_D20230612-20230612"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-12</xbrli:startDate><xbrli:endDate>2023-06-12</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i50f9c321473f42f699ab6ffb81ffd1a8_1"></div><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:8pt;text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">WASHINGTON, DC 20549</span></div><div style="margin-top:8pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i1dae0cffe7ba4799a527dae2c57b0859_D20230612-20230612" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjUwZjljMzIxNDczZjQyZjY5OWFiNmZmYjgxZmZkMWE4L3NlYzo1MGY5YzMyMTQ3M2Y0MmY2OTlhYjZmZmI4MWZmZDFhOF8xL2ZyYWc6NGJjYTBkOGQ3OWFmNDNkN2I4MWYyNTJlNWEwYjA0NDEvdGV4dHJlZ2lvbjo0YmNhMGQ4ZDc5YWY0M2Q3YjgxZjI1MmU1YTBiMDQ0MV8xMzAy_2bff1795-c87e-4f86-bbcb-c11654d6491c">8-K</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">CURRENT REPORT PURSUANT</span></div><div style="text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">TO SECTION 13 OR 15(d) OF THE</span></div><div style="text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Date of report (Date of earliest event reported): </span><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i1dae0cffe7ba4799a527dae2c57b0859_D20230612-20230612" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjUwZjljMzIxNDczZjQyZjY5OWFiNmZmYjgxZmZkMWE4L3NlYzo1MGY5YzMyMTQ3M2Y0MmY2OTlhYjZmZmI4MWZmZDFhOF8xL2ZyYWc6NGJjYTBkOGQ3OWFmNDNkN2I4MWYyNTJlNWEwYjA0NDEvdGV4dHJlZ2lvbjo0YmNhMGQ4ZDc5YWY0M2Q3YjgxZjI1MmU1YTBiMDQ0MV8yMjM_be48fbeb-c8ea-4c38-b45e-e6fdd44b8702">June 12, 2023</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i1dae0cffe7ba4799a527dae2c57b0859_D20230612-20230612" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjUwZjljMzIxNDczZjQyZjY5OWFiNmZmYjgxZmZkMWE4L3NlYzo1MGY5YzMyMTQ3M2Y0MmY2OTlhYjZmZmI4MWZmZDFhOF8xL2ZyYWc6NGJjYTBkOGQ3OWFmNDNkN2I4MWYyNTJlNWEwYjA0NDEvdGV4dHJlZ2lvbjo0YmNhMGQ4ZDc5YWY0M2Q3YjgxZjI1MmU1YTBiMDQ0MV8xMzA2_2dd9dadd-e5aa-48da-a73b-11abc7b7f979">KIORA PHARMACEUTICALS, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i1dae0cffe7ba4799a527dae2c57b0859_D20230612-20230612" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjUwZjljMzIxNDczZjQyZjY5OWFiNmZmYjgxZmZkMWE4L3NlYzo1MGY5YzMyMTQ3M2Y0MmY2OTlhYjZmZmI4MWZmZDFhOF8xL2ZyYWc6NGJjYTBkOGQ3OWFmNDNkN2I4MWYyNTJlNWEwYjA0NDEvdGV4dHJlZ2lvbjo0YmNhMGQ4ZDc5YWY0M2Q3YjgxZjI1MmU1YTBiMDQ0MV8xMzEy_b1d77c16-852d-4f08-b11a-c3a30845949e">Delaware</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(State or other jurisdiction of incorporation)</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i1dae0cffe7ba4799a527dae2c57b0859_D20230612-20230612" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjUwZjljMzIxNDczZjQyZjY5OWFiNmZmYjgxZmZkMWE4L3NlYzo1MGY5YzMyMTQ3M2Y0MmY2OTlhYjZmZmI4MWZmZDFhOF8xL2ZyYWc6NGJjYTBkOGQ3OWFmNDNkN2I4MWYyNTJlNWEwYjA0NDEvdGFibGU6MWIzNzU5MDZmNTkxNDczYmFlZDgyOGViNmJhNGM1Y2UvdGFibGVyYW5nZToxYjM3NTkwNmY1OTE0NzNiYWVkODI4ZWI2YmE0YzVjZV8wLTAtMS0xLTQyNjE4_e7ce04dd-1eb2-4154-8069-abbbefa40d30">001-36672</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i1dae0cffe7ba4799a527dae2c57b0859_D20230612-20230612" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjUwZjljMzIxNDczZjQyZjY5OWFiNmZmYjgxZmZkMWE4L3NlYzo1MGY5YzMyMTQ3M2Y0MmY2OTlhYjZmZmI4MWZmZDFhOF8xL2ZyYWc6NGJjYTBkOGQ3OWFmNDNkN2I4MWYyNTJlNWEwYjA0NDEvdGFibGU6MWIzNzU5MDZmNTkxNDczYmFlZDgyOGViNmJhNGM1Y2UvdGFibGVyYW5nZToxYjM3NTkwNmY1OTE0NzNiYWVkODI4ZWI2YmE0YzVjZV8wLTEtMS0xLTQyNjE4_bf1d6144-4b1a-4c4e-b5aa-b5915a26affc">98-0443284</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(IRS Employer Identification No.)</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i1dae0cffe7ba4799a527dae2c57b0859_D20230612-20230612" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjUwZjljMzIxNDczZjQyZjY5OWFiNmZmYjgxZmZkMWE4L3NlYzo1MGY5YzMyMTQ3M2Y0MmY2OTlhYjZmZmI4MWZmZDFhOF8xL2ZyYWc6NGJjYTBkOGQ3OWFmNDNkN2I4MWYyNTJlNWEwYjA0NDEvdGV4dHJlZ2lvbjo0YmNhMGQ4ZDc5YWY0M2Q3YjgxZjI1MmU1YTBiMDQ0MV8xMzA0_5ee33721-e45c-4ec6-80d3-395bd099bc34">332 Encinitas Blvd.</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i1dae0cffe7ba4799a527dae2c57b0859_D20230612-20230612" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjUwZjljMzIxNDczZjQyZjY5OWFiNmZmYjgxZmZkMWE4L3NlYzo1MGY5YzMyMTQ3M2Y0MmY2OTlhYjZmZmI4MWZmZDFhOF8xL2ZyYWc6NGJjYTBkOGQ3OWFmNDNkN2I4MWYyNTJlNWEwYjA0NDEvdGV4dHJlZ2lvbjo0YmNhMGQ4ZDc5YWY0M2Q3YjgxZjI1MmU1YTBiMDQ0MV8xMzEw_4c5543f0-af57-491f-a1b8-4f1ba5a2e993">Suite 102</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i1dae0cffe7ba4799a527dae2c57b0859_D20230612-20230612" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjUwZjljMzIxNDczZjQyZjY5OWFiNmZmYjgxZmZkMWE4L3NlYzo1MGY5YzMyMTQ3M2Y0MmY2OTlhYjZmZmI4MWZmZDFhOF8xL2ZyYWc6NGJjYTBkOGQ3OWFmNDNkN2I4MWYyNTJlNWEwYjA0NDEvdGV4dHJlZ2lvbjo0YmNhMGQ4ZDc5YWY0M2Q3YjgxZjI1MmU1YTBiMDQ0MV8xMzE1_b8bde44d-1966-496a-bb0a-af429d61caba">Encinitas</ix:nonNumeric>,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i1dae0cffe7ba4799a527dae2c57b0859_D20230612-20230612" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjUwZjljMzIxNDczZjQyZjY5OWFiNmZmYjgxZmZkMWE4L3NlYzo1MGY5YzMyMTQ3M2Y0MmY2OTlhYjZmZmI4MWZmZDFhOF8xL2ZyYWc6NGJjYTBkOGQ3OWFmNDNkN2I4MWYyNTJlNWEwYjA0NDEvdGV4dHJlZ2lvbjo0YmNhMGQ4ZDc5YWY0M2Q3YjgxZjI1MmU1YTBiMDQ0MV8xMzA5_d5605d37-18e3-4783-bd6c-0f570906d767">CA</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i1dae0cffe7ba4799a527dae2c57b0859_D20230612-20230612" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjUwZjljMzIxNDczZjQyZjY5OWFiNmZmYjgxZmZkMWE4L3NlYzo1MGY5YzMyMTQ3M2Y0MmY2OTlhYjZmZmI4MWZmZDFhOF8xL2ZyYWc6NGJjYTBkOGQ3OWFmNDNkN2I4MWYyNTJlNWEwYjA0NDEvdGV4dHJlZ2lvbjo0YmNhMGQ4ZDc5YWY0M2Q3YjgxZjI1MmU1YTBiMDQ0MV80MTQ_91c418b4-3997-45d6-8985-e661891ca6c8">92024</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i1dae0cffe7ba4799a527dae2c57b0859_D20230612-20230612" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjUwZjljMzIxNDczZjQyZjY5OWFiNmZmYjgxZmZkMWE4L3NlYzo1MGY5YzMyMTQ3M2Y0MmY2OTlhYjZmZmI4MWZmZDFhOF8xL2ZyYWc6NGJjYTBkOGQ3OWFmNDNkN2I4MWYyNTJlNWEwYjA0NDEvdGV4dHJlZ2lvbjo0YmNhMGQ4ZDc5YWY0M2Q3YjgxZjI1MmU1YTBiMDQ0MV80MTg_54acb35f-46f3-4dbc-9aeb-d5e555f5a093">858</ix:nonNumeric>) <ix:nonNumeric contextRef="i1dae0cffe7ba4799a527dae2c57b0859_D20230612-20230612" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjUwZjljMzIxNDczZjQyZjY5OWFiNmZmYjgxZmZkMWE4L3NlYzo1MGY5YzMyMTQ3M2Y0MmY2OTlhYjZmZmI4MWZmZDFhOF8xL2ZyYWc6NGJjYTBkOGQ3OWFmNDNkN2I4MWYyNTJlNWEwYjA0NDEvdGV4dHJlZ2lvbjo0YmNhMGQ4ZDc5YWY0M2Q3YjgxZjI1MmU1YTBiMDQ0MV8xMzA1_7384835e-f3ab-46a9-863a-15f0599c0407">224-9600</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Former name or former address, if changed since last report)</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:1.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.870%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1dae0cffe7ba4799a527dae2c57b0859_D20230612-20230612" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjUwZjljMzIxNDczZjQyZjY5OWFiNmZmYjgxZmZkMWE4L3NlYzo1MGY5YzMyMTQ3M2Y0MmY2OTlhYjZmZmI4MWZmZDFhOF8xL2ZyYWc6NGJjYTBkOGQ3OWFmNDNkN2I4MWYyNTJlNWEwYjA0NDEvdGFibGU6Njg2NjU2YTI1OGNjNDc4ZTk4OWU3NGU3ODFhNmIwODYvdGFibGVyYW5nZTo2ODY2NTZhMjU4Y2M0NzhlOTg5ZTc0ZTc4MWE2YjA4Nl8wLTAtMS0xLTQyNjE4_8dbffde0-b9ff-40fc-a2b5-eaf16deeb473">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1dae0cffe7ba4799a527dae2c57b0859_D20230612-20230612" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjUwZjljMzIxNDczZjQyZjY5OWFiNmZmYjgxZmZkMWE4L3NlYzo1MGY5YzMyMTQ3M2Y0MmY2OTlhYjZmZmI4MWZmZDFhOF8xL2ZyYWc6NGJjYTBkOGQ3OWFmNDNkN2I4MWYyNTJlNWEwYjA0NDEvdGFibGU6Njg2NjU2YTI1OGNjNDc4ZTk4OWU3NGU3ODFhNmIwODYvdGFibGVyYW5nZTo2ODY2NTZhMjU4Y2M0NzhlOTg5ZTc0ZTc4MWE2YjA4Nl8yLTAtMS0xLTQyNjE4_3f1eb3a8-f9bb-4d0f-9005-e49663e06f39">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1dae0cffe7ba4799a527dae2c57b0859_D20230612-20230612" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjUwZjljMzIxNDczZjQyZjY5OWFiNmZmYjgxZmZkMWE4L3NlYzo1MGY5YzMyMTQ3M2Y0MmY2OTlhYjZmZmI4MWZmZDFhOF8xL2ZyYWc6NGJjYTBkOGQ3OWFmNDNkN2I4MWYyNTJlNWEwYjA0NDEvdGFibGU6Njg2NjU2YTI1OGNjNDc4ZTk4OWU3NGU3ODFhNmIwODYvdGFibGVyYW5nZTo2ODY2NTZhMjU4Y2M0NzhlOTg5ZTc0ZTc4MWE2YjA4Nl80LTAtMS0xLTQyNjE4_71300be7-f4cf-4452-949d-597e4d487e38">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1dae0cffe7ba4799a527dae2c57b0859_D20230612-20230612" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjUwZjljMzIxNDczZjQyZjY5OWFiNmZmYjgxZmZkMWE4L3NlYzo1MGY5YzMyMTQ3M2Y0MmY2OTlhYjZmZmI4MWZmZDFhOF8xL2ZyYWc6NGJjYTBkOGQ3OWFmNDNkN2I4MWYyNTJlNWEwYjA0NDEvdGFibGU6Njg2NjU2YTI1OGNjNDc4ZTk4OWU3NGU3ODFhNmIwODYvdGFibGVyYW5nZTo2ODY2NTZhMjU4Y2M0NzhlOTg5ZTc0ZTc4MWE2YjA4Nl82LTAtMS0xLTQyNjE4_38d1facc-cc25-48a7-99e2-3b537510de13">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-top:8pt;text-align:justify"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.203%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.204%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1dae0cffe7ba4799a527dae2c57b0859_D20230612-20230612" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjUwZjljMzIxNDczZjQyZjY5OWFiNmZmYjgxZmZkMWE4L3NlYzo1MGY5YzMyMTQ3M2Y0MmY2OTlhYjZmZmI4MWZmZDFhOF8xL2ZyYWc6NGJjYTBkOGQ3OWFmNDNkN2I4MWYyNTJlNWEwYjA0NDEvdGFibGU6NDNlN2ViNjEwMzM4NDJjYzhiZmM1MjNiNjIxMWE1ODMvdGFibGVyYW5nZTo0M2U3ZWI2MTAzMzg0MmNjOGJmYzUyM2I2MjExYTU4M18xLTAtMS0xLTQyNjE4_761545d6-2971-45eb-a8df-f19c596fe894">Common Stock, $0.01 par value</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1dae0cffe7ba4799a527dae2c57b0859_D20230612-20230612" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjUwZjljMzIxNDczZjQyZjY5OWFiNmZmYjgxZmZkMWE4L3NlYzo1MGY5YzMyMTQ3M2Y0MmY2OTlhYjZmZmI4MWZmZDFhOF8xL2ZyYWc6NGJjYTBkOGQ3OWFmNDNkN2I4MWYyNTJlNWEwYjA0NDEvdGFibGU6NDNlN2ViNjEwMzM4NDJjYzhiZmM1MjNiNjIxMWE1ODMvdGFibGVyYW5nZTo0M2U3ZWI2MTAzMzg0MmNjOGJmYzUyM2I2MjExYTU4M18xLTItMS0xLTQyNjE4_07eac58d-657c-4d9d-967f-fd27060c73f0">KPRX</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1dae0cffe7ba4799a527dae2c57b0859_D20230612-20230612" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjUwZjljMzIxNDczZjQyZjY5OWFiNmZmYjgxZmZkMWE4L3NlYzo1MGY5YzMyMTQ3M2Y0MmY2OTlhYjZmZmI4MWZmZDFhOF8xL2ZyYWc6NGJjYTBkOGQ3OWFmNDNkN2I4MWYyNTJlNWEwYjA0NDEvdGFibGU6NDNlN2ViNjEwMzM4NDJjYzhiZmM1MjNiNjIxMWE1ODMvdGFibGVyYW5nZTo0M2U3ZWI2MTAzMzg0MmNjOGJmYzUyM2I2MjExYTU4M18xLTQtMS0xLTQyNjE4_decc6269-0e76-49cc-885d-e4ebf2cda371">NASDAQ</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:8pt;text-align:justify"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Emerging growth company </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i1dae0cffe7ba4799a527dae2c57b0859_D20230612-20230612" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjUwZjljMzIxNDczZjQyZjY5OWFiNmZmYjgxZmZkMWE4L3NlYzo1MGY5YzMyMTQ3M2Y0MmY2OTlhYjZmZmI4MWZmZDFhOF8xL2ZyYWc6NGJjYTBkOGQ3OWFmNDNkN2I4MWYyNTJlNWEwYjA0NDEvdGV4dHJlZ2lvbjo0YmNhMGQ4ZDc5YWY0M2Q3YjgxZjI1MmU1YTBiMDQ0MV8xMzE2_5f3bf06b-3061-4b61-985f-a57b794662e4">&#9744;</ix:nonNumeric> </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i1dae0cffe7ba4799a527dae2c57b0859_D20230612-20230612" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjUwZjljMzIxNDczZjQyZjY5OWFiNmZmYjgxZmZkMWE4L3NlYzo1MGY5YzMyMTQ3M2Y0MmY2OTlhYjZmZmI4MWZmZDFhOF8xL2ZyYWc6NGJjYTBkOGQ3OWFmNDNkN2I4MWYyNTJlNWEwYjA0NDEvdGV4dHJlZ2lvbjo0YmNhMGQ4ZDc5YWY0M2Q3YjgxZjI1MmU1YTBiMDQ0MV8xMjk5_5f3bf06b-3061-4b61-985f-a57b794662e4">&#9744;</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i50f9c321473f42f699ab6ffb81ffd1a8_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Item 1.01.&#160;&#160;&#160;&#160;Entry into a Material Definitive Agreement.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As previously reported, on September 26, 2018, Kiora Pharmaceuticals, Inc. (the &#8220;Company&#8221;) entered into an Intellectual Property License Agreement (the &#8220;2018 Agreement&#8221;) with Sentrx Animal Care, Inc. (&#8220;Sentrx&#8221;), with respect to certain rights relating to the manufacturing of the Company&#8217;s KIO-201 product candidate.  Under the 2018 Agreement, Sentrx granted to the Company an exclusive license to use Sentrx&#8217;s procedures, trade secrets, know-how and other relevant intellectual property in connection with the production of KIO-201.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In connection with the 2018 Agreement, the Company paid Sentrx an upfront payment of $250,000 and agreed to pay Sentrx milestone payments totaling up to $4.75 million (the &#8220;Milestone Payments&#8221;), upon and subject to the achievement of certain specified developmental and commercial milestones. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On June 12, 2023 and effective as of June 7, 2023 (the &#8220;Effective Date&#8221;), the Company and Sentrx entered into a First Amendment to the 2018 Agreement (the &#8220;Amendment&#8221;).</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pursuant to the Amendment, among other things, the Company is no longer obligated to pay any of the Milestone Payments.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Also on June 12, 2023 and effective as of the Effective Date, the Company and Sentrx entered into an Exclusive License Agreement (the &#8220;2023 Agreement&#8221;).</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pursuant to the 2023 Agreement, the Company granted to Sentrx an exclusive and sublicensable license to certain patents related to KIO-201 in the field of animal health for diseases or conditions of the eye and its adnexa, and Sentrx is obligated to pay to the Company a low single-digit royalty on net sales of products covered by the licensed patents. The license granted by the 2023 Agreement will remain in effect for the duration of the licensed patents unless earlier terminated in accordance with its terms.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The foregoing descriptions of the Amendment and the 2023 Agreement do not purport to be complete descriptions of all of the terms of the Amendment and the 2023 Agreement, and are qualified in their entirety by reference to the full text of the Amendment and the 2023 Agreement, copies of which are filed as Exhibit 10.1 and Exhibit 10.2 hereto, respectively. </span></div><div style="text-align:justify"><span><br/></span></div><div id="i50f9c321473f42f699ab6ffb81ffd1a8_13"></div><div style="-sec-extract:summary;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Item 8.01 Other Events.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On June 15, 2023, the Company issued a press release announcing the Amendment and the 2023 Agreement, a copy of which is attached as Exhibit 99.1 to this Current Report and is incorporated herein by reference.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Information contained on or accessible through any website reference in the press releases is not part of, or incorporated by reference in, this Current Report, and the inclusion of such website addresses in this Current Report by incorporation by reference of the press releases is an inactive textual references only.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i50f9c321473f42f699ab6ffb81ffd1a8_16"></div><div style="-sec-extract:summary;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01 Financial Statements and Exhibits</span></div><div style="margin-top:10pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(d)</span><span style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:0.74pt"> Exhibits.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit&#160;<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title</span></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.1&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit101.htm">First Amendment to Intellectual Property License Agreement, dated as of June 12, 2023, between Kiora Pharmaceuticals, Inc. and Sentrx Animal Care, Inc.</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.2&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit102.htm">Exclusive License Agreement, dated as of June 12, 2023, between Kiora Pharmaceuticals, Inc. and Sentrx Animal Care, Inc.</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit991-pressreleasejun.htm">Press Release of Kiora Pharmaceuticals, Inc., dated as of June 15, 2023</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8224; Certain confidential portions of this exhibit were omitted pursuant to Item 601(b)(2)(ii) of Regulation S-K because the identified confidential portions (i) are not material and (ii) are customarily and actually treated as private or confidential by the Company.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i50f9c321473f42f699ab6ffb81ffd1a8_19"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.841%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">KIORA PHARMACEUTICALS, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Brian M. Strem, Ph.D.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brian M. Strem, Ph.D.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal executive officer)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: June 15, 2023</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
[{"type": "8-K", "sequence": "1", "filename": "kprx-20230612.htm", "description": "8-K", "secsgml_size_bytes": 40207}]
{"company-data": {"conformed-name": "KIORA PHARMACEUTICALS INC", "cik": "0001372514", "assigned-sic": "2834", "irs-number": "000000000", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-36672", "film-number": "231018199"}, "business-address": {"street1": "332 ENCINITAS BOULEVARD", "street2": "SUITE 102", "city": "ENCINITAS", "state": "CA", "zip": "92024", "phone": "781-788-8869"}, "mail-address": {"street1": "332 ENCINITAS BOULEVARD", "street2": "SUITE 102", "city": "ENCINITAS", "state": "CA", "zip": "92024"}, "former-company": {"former-conformed-name": "EYEGATE PHARMACEUTICALS INC", "date-changed": "20060811"}}
kprx-20230612
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM
8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported):
June 12, 2023
KIORA PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation)
001-36672
98-0443284
(Commission File Number)
(IRS Employer Identification No.)
332 Encinitas Blvd.
Suite 102
Encinitas
,
CA
92024
(
858
)
224-9600
(Registrant's telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class:
Trading Symbol(s)
Name of each exchange on which registered:
Common Stock, $0.01 par value
KPRX
NASDAQ
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Item 1.01.    Entry into a Material Definitive Agreement.
As previously reported, on September 26, 2018, Kiora Pharmaceuticals, Inc. (the "Company") entered into an Intellectual Property License Agreement (the "2018 Agreement") with Sentrx Animal Care, Inc. ("Sentrx"), with respect to certain rights relating to the manufacturing of the Company's KIO-201 product candidate.  Under the 2018 Agreement, Sentrx granted to the Company an exclusive license to use Sentrx's procedures, trade secrets, know-how and other relevant intellectual property in connection with the production of KIO-201.
In connection with the 2018 Agreement, the Company paid Sentrx an upfront payment of $250,000 and agreed to pay Sentrx milestone payments totaling up to $4.75 million (the "Milestone Payments"), upon and subject to the achievement of certain specified developmental and commercial milestones.
On June 12, 2023 and effective as of June 7, 2023 (the "Effective Date"), the Company and Sentrx entered into a First Amendment to the 2018 Agreement (the "Amendment").
Pursuant to the Amendment, among other things, the Company is no longer obligated to pay any of the Milestone Payments.
Also on June 12, 2023 and effective as of the Effective Date, the Company and Sentrx entered into an Exclusive License Agreement (the "2023 Agreement").
Pursuant to the 2023 Agreement, the Company granted to Sentrx an exclusive and sublicensable license to certain patents related to KIO-201 in the field of animal health for diseases or conditions of the eye and its adnexa, and Sentrx is obligated to pay to the Company a low single-digit royalty on net sales of products covered by the licensed patents. The license granted by the 2023 Agreement will remain in effect for the duration of the licensed patents unless earlier terminated in accordance with its terms.
The foregoing descriptions of the Amendment and the 2023 Agreement do not purport to be complete descriptions of all of the terms of the Amendment and the 2023 Agreement, and are qualified in their entirety by reference to the full text of the Amendment and the 2023 Agreement, copies of which are filed as Exhibit 10.1 and Exhibit 10.2 hereto, respectively.
Item 8.01 Other Events.
On June 15, 2023, the Company issued a press release announcing the Amendment and the 2023 Agreement, a copy of which is attached as Exhibit 99.1 to this Current Report and is incorporated herein by reference.
Information contained on or accessible through any website reference in the press releases is not part of, or incorporated by reference in, this Current Report, and the inclusion of such website addresses in this Current Report by incorporation by reference of the press releases is an inactive textual references only.
Item 9.01 Financial Statements and Exhibits
(d)
Exhibits.
Exhibit
Number
Title
10.1†
First Amendment to Intellectual Property License Agreement, dated as of June 12, 2023, between Kiora Pharmaceuticals, Inc. and Sentrx Animal Care, Inc.
10.2†
Exclusive License Agreement, dated as of June 12, 2023, between Kiora Pharmaceuticals, Inc. and Sentrx Animal Care, Inc.
99.1
Press Release of Kiora Pharmaceuticals, Inc., dated as of June 15, 2023
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
† Certain confidential portions of this exhibit were omitted pursuant to Item 601(b)(2)(ii) of Regulation S-K because the identified confidential portions (i) are not material and (ii) are customarily and actually treated as private or confidential by the Company.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
KIORA PHARMACEUTICALS, INC.
By:
/s/ Brian M. Strem, Ph.D.
Brian M. Strem, Ph.D.
President and Chief Executive Officer
(Principal executive officer)
Date: June 15, 2023